|
1
|
Geremia A, Biancheri P, Allan P, Corazza
GR and Di Sabatino A: Innate and adaptive immunity in inflammatory
bowel disease. Autoimmun Rev. 13:3–10. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Dothel G, Vasina V, Barbara G and De Ponti
F: Animal models of chemically induced intestinal inflammation:
Predictivity and ethical issues. Pharmacol Ther. 139:71–86. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Molodecky NA, Soon IS, Rabi DM, Ghali WA,
Ferris M, Chernoff G, Benchimol EI, Panaccione R, Ghosh S, Barkema
HW and Kaplan GG: Increasing incidence and prevalence of the
inflammatory bowel diseases with time, based on systematic review.
Gastroenterology. 142:46–54.e42; quiz e30. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Prideaux L, Kamm MA, De Cruz PP, Chan FK
and Ng SC: Inflammatory bowel disease in Asia: A systematic review.
J Gastroenterol Hepatol. 27:1266–1280. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zou Y, Li WY, Wan Z, Zhao B, He ZW, Wu ZG,
Huang GL, Wang J, Li BB, Lu YJ, et al: Huangqin-tang ameliorates
TNBS-induced colitis by regulating effector and regulatory CD4 (+)
T cells. Biomed Res Int. 2015:1020212015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Strober W, Fuss I and Mannon P: The
fundamental basis of inflammatory bowel disease. J Clin Invest.
117:514–521. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Matricon J, Barnich N and Ardid D:
Immunopathogenesis of inflammatory bowel disease. Self Nonself.
1:299–309. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Maynard CL and Weaver CT: Intestinal
effector T cells in health and disease. Immunity. 31:389–400. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhu J, Yamane H and Paul WE:
Differentiation of effector CD4 T cell populations (*). Annu Rev
Immunol. 28:445–489. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Almeida Cde S, Andrade-Oliveira V, Câmara
NO, Jacysyn JF and Faquim-Mauro EL: Crotoxin from crotalus durissus
terrificus is able to down-modulate the acute intestinal
inflammation in mice. PLoS One. 10:e01214272015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Dambacher J, Beigel F, Zitzmann K, De Toni
EN, Göke B, Diepolder HM, Auernhammer CJ and Brand S: The role of
the novel Th17 cytokine IL-26 in intestinal inflammation. Gut.
58:1207–1217. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Geremia A and Jewell DP: The IL-23/IL-17
pathway in inflammatory bowel disease. Expert Rev Gastroenterol
Hepatol. 6:223–237. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Valencia X, Stephens G, Goldbach-Mansky R,
Wilson M, Shevach EM and Lipsky PE: TNF downmodulates the function
of human CD4+CD25hi T-regulatory cells. Blood. 108:253–261. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Khor B, Gardet A and Xavier RJ: Genetics
and pathogenesis of inflammatory bowel disease. Nature.
474:307–317. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cătană CS, Neagoe I Berindan, Cozma V,
Magdaş C, Tăbăran F and Dumitraşcu DL: Contribution of the
IL-17/IL-23 axis to the pathogenesis of inflammatory bowel disease.
World J Gastroenterol. 21:5823–5830. 2015.PubMed/NCBI
|
|
16
|
Himmel ME, Hardenberg G, Piccirillo CA,
Steiner TS and Levings MK: The role of T-regulatory cells and
Toll-like receptors in the pathogenesis of human inflammatory bowel
disease. Immunology. 128:145–153. 2008. View Article : Google Scholar
|
|
17
|
Chruscinski A, Sadozai H, Rojas-Luengas V,
Bartczak A, Khattar R, Selzner N and Levy GA: Role of regulatory T
cells (Treg) and the treg effector molecule fibrinogen-like protein
2 in alloimmunity and autoimmunity. Rambam Maimonides Med J.
6:2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bilate AM and Lafaille JJ: Induced
CD4+Foxp3+ regulatory T cells in immune tolerance. Annu Rev
Immunol. 30:733–758. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Joller N, Lozano E, Burkett PR, Patel B,
Xiao S, Zhu C, Xia J, Tan TG, Sefik E, Yajnik V, et al: Treg cells
expressing the coinhibitory molecule TIGIT selectively inhibit
proinflammatory Th1 and Th17 cell responses. Immunity. 40:569–581.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Shalev I, Liu H, Koscik C, Bartczak A,
Javadi M, Wong KM, Maknojia A, He W, Liu MF, Diao J, et al:
Targeted deletion of fgl2 leads to impaired regulatory T cell
activity and development of autoimmune glomerulonephritis. J
Immunol. 180:249–260. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chan CW, Kay LS, Khadaroo RG, Chan MW,
Lakatoo S, Young KJ, Zhang L, Gorczynski RM, Cattral M, Rotstein O
and Levy GA: Soluble fibrinogen-like protein 2/fibroleukin exhibits
immunosuppressive properties: Suppressing T cell proliferation and
inhibiting maturation of bone marrow-derived dendritic cells. J
Immunol. 170:4036–4044. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Dong X, Ye X, Chen X, Chen T, Xie S, Li Q,
Lin X and Huang Z: Intestinal and peripheral fibrinogen-like
protein 2 expression in inflammatory bowel disease. Dig Dis Sci.
59:769–777. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Alex P, Zachos NC, Nguyen T, Gonzales L,
Chen TE, Conklin LS, Centola M and Li X: Distinct cytokine patterns
identified from multiplex profiles of murine DSS and TNBS-induced
colitis. Inflamm Bowel Dis. 15:341–352. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wirtz S, Neufert C, Weigmann B and Neurath
MF: Chemically induced mouse models of intestinal inflammation. Nat
Protoc. 7:541–546. 2007. View Article : Google Scholar
|
|
25
|
Glauben R, Batra A, Stroh T, Erben U,
Fedke I, Lehr HA, Leoni F, Mascagni P, Dinarello CA, Zeitz M and
Siegmund B: Histone deacetylases: Novel targets for prevention of
colitis-associated cancer in mice. Gut. 57:613–622. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Bell CJ, Gall DG and Wallace JL:
Disruption of colonic electrolyte transport in experimental
colitis. Am J Physiol. 268:G622–G630. 1995.PubMed/NCBI
|
|
27
|
Scheiffele F and Fuss IJ: Induction of
TNBS colitis in mice. Curr Protoc Immunol: Chapter. 15:Unit 15. 19.
2002. View Article : Google Scholar
|
|
28
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Eastaff-Leung N, Mabarrack N, Barbour A,
Cummins A and Barry S: Foxp3+ regulatory T cells, Th17 effector
cells, and cytokine environment in inflammatory bowel disease. J
Clin Immunol. 30:80–89. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chaudhry A, Rudra D, Treuting P, Samstein
RM, Liang Y, Kas A and Rudensky AY: CD4+ regulatory T cells control
TH17 responses in a Stat3-dependent manner. Science. 326:986–991.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kaser A, Zeissig S and Blumberg RS:
Inflammatory bowel disease. Annu Rev Immunol. 28:573–621. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Veltkamp C, Anstaett M, Wahl K, Möller S,
Gangl S, Bachmann O, Hardtke-Wolenski M, Länger F, Stremmel W,
Manns MP, et al: Apoptosis of regulatory T lymphocytes is increased
in chronic inflammatory bowel disease and reversed by anti-TNFα
treatment. Gut. 60:1345–1353. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Brand S: Crohn's disease: Th1, Th17 or
both? the change of a paradigm: New immunological and genetic
insights implicate Th17 cells in the pathogenesis of Crohn's
disease. Gut. 58:1152–1167. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kugathasan S, Saubermann LJ, Smith L, Kou
D, Itoh J, Binion DG, Levine AD, Blumberg RS and Fiocchi C: Mucosal
T-cell immunoregulation varies in early and late inflammatory bowel
disease. Gut. 56:1696–1705. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wilson NJ, Boniface K, Chan JR, McKenzie
BS, Blumenschein WM, Mattson JD, Basham B, Smith K, Chen T, Morel
F, et al: Development, cytokine profile and function of human
interleukin 17-producing helper T cells. Nat Immunol. 8:950–957.
2007. View
Article : Google Scholar : PubMed/NCBI
|
|
36
|
Vignali DA, Collison LW and Workman CJ:
How regulatory T cells work. Nat Rev Immunol. 8:523–532. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Maul J, Loddenkemper C, Mundt P, Berg E,
Giese T, Stallmach A, Zeitz M and Duchmann R: Peripheral and
intestinal regulatory CD4+CD25high T cells in inflammatory bowel
disease. Gastroenterology. 128:1868–1878. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Hori S, Nomura T and Sakaguchi S: Control
of regulatory T cell development by the transcription factor Foxp3.
Science. 299:1057–1061. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Shalev I, Wong KM, Foerster K, Zhu Y, Chan
C, Maknojia A, Zhang J, Ma XZ, Yang XC, Gao JF, et al: The novel
CD4+CD25+ regulatory T cell effector molecule fibrinogen-like
protein 2 contributes to the outcome of murine fulminant viral
hepatitis. Hepatology. 49:387–397. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Miyara M and Sakaguchi S: Natural
regulatory T cells: Mechanisms of suppression. Trends Mol Med.
13:108–116. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Foerster K, Helmy A, Zhu Y, Khattar R,
Adeyi OA, Wong KM, Shalev I, Clark DA, Wong PY, Heathcote EJ, et
al: The novel immunoregulatory molecule FGL2: A potential biomarker
for severity of chronic hepatitis C virus infection. J Hepatol.
53:608–615. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Liu H, Shalev I, Manuel J, He W, Leung E,
Crookshank J, Liu MF, Diao J, Cattral M, Clark DA, et al: The
FGL2-FcgammaRIIB pathway: A novel mechanism leading to
immunosuppression. Eur J Immunol. 38:3114–3126. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Bettelli E, Carrier Y, Gao W, Korn T,
Strom TB, Oukka M, Weiner HL and Kuchroo VK: Reciprocal
developmental pathways for the generation of pathogenic effector
TH17 and regulatory T cells. Nature. 441:235–238. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Elshal MF, Aldahlawi AM, Saadah OI and
McCoy JP: Reduced dendritic cells expressing CD200R1 in children
with inflammatory bowel disease: Correlation with Th17 and
regulatory T cells. Int J Mol Sci. 16:28998–29010. 2015. View Article : Google Scholar : PubMed/NCBI
|
